The company has been funded to date by its directors and a number of  private investors. In addition, grants have been received from the Welsh Assembly Government's SMARTCymru programme and from a local Powys fund - Glasu.

The business has aroused international interest – mainly as a result of awareness marketing – because of the daffodil being the iconic Welsh national flower, the parlous state of Welsh upland farming and the spectacular local scenery. Alzeim has been featured on various television channels, and numerous press articles have been published.  Publicity has also been generated by supportive pressure groups wanting more action to curb the ravages of Alzheimer’s Disease.

Alzeim’s product strategy is divided into four phases. The first is the production of natural Galanthamine from its specially grown daffodil crops; the second is the production of a range of Galanthamine-based products – some with unusual drug-delivery systems - for the generic prescription market due to open up in 2009; the third will be to develop Galanthamine-based, safe products for the health market sector and the fourth will feature other alkaloids and possibly other medical conditions.

The first phase involves the complete agronomic processing regime  - using tonnes of specific varieties of daffodils including their planting, fertilizing, growth control, harvesting and ultimate extraction.